Does the media prefer CAPR or MIRM?

In the previous week, Capricor Therapeutics had 7 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 11 mentions for Capricor Therapeutics and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.18 beat Capricor Therapeutics' score of 0.39 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, CAPR or CNTA?

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capricor Therapeutics N/A N/A -$105.04M -$2.32 N/A Centessa Pharmaceuticals N/A N/A -$197.53M -$1.79 N/A

Is CAPR or CNTA more profitable?

Capricor Therapeutics' return on equity of -59.27% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Centessa Pharmaceuticals N/A -60.37% -44.17%

Does the media prefer RYTM or CAPR?

In the previous week, Capricor Therapeutics had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 11 mentions for Capricor Therapeutics and 5 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.61 beat Capricor Therapeutics' score of 0.39 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, CAPR or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capricor Therapeutics N/A N/A -$105.04M -$2.32 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is CAPR or BLTE more profitable?

Belite Bio's return on equity of -13.14% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Belite Bio N/A -13.14% -12.88%

Does the media refer more to CAPR or BLTE?

In the previous week, Capricor Therapeutics had 9 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for Capricor Therapeutics and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.57 beat Capricor Therapeutics' score of 0.39 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, COGT or CAPR?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Capricor Therapeutics N/A N/A -$105.04M -$2.32 N/A

Is COGT or CAPR more profitable?

Capricor Therapeutics' return on equity of -59.27% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Capricor Therapeutics N/A -59.27% -48.65%

Does the media prefer COGT or CAPR?

In the previous week, Capricor Therapeutics had 9 more articles in the media than Cogent Biosciences. MarketBeat recorded 11 mentions for Capricor Therapeutics and 2 mentions for Cogent Biosciences. Capricor Therapeutics' average media sentiment score of 0.39 beat Cogent Biosciences' score of 0.38 indicating that Capricor Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Capricor Therapeutics (CAPR) Competitors

$23.91 -2.53 (-9.57%)

As of 12:22 PM Eastern

Compare

CAPR vs. MIRM, CNTA, RYTM, BLTE, and COGT

Should you buy Capricor Therapeutics stock or one of its competitors? MarketBeat compares Capricor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Capricor Therapeutics include Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), Rhythm Pharmaceuticals (RYTM), Belite Bio (BLTE), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Capricor Therapeutics compare to Mirum Pharmaceuticals?

Capricor Therapeutics (NASDAQ:CAPR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Capricor Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Mirum Pharmaceuticals	$521.31M	14.37	-$23.36M	-$13.61	N/A

21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Capricor Therapeutics presently has a consensus price target of $50.30, indicating a potential upside of 110.37%. Mirum Pharmaceuticals has a consensus price target of $139.80, indicating a potential upside of 13.84%. Given Capricor Therapeutics' higher probable upside, research analysts clearly believe Capricor Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Capricor Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

In the previous week, Capricor Therapeutics had 7 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 11 mentions for Capricor Therapeutics and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.18 beat Capricor Therapeutics' score of 0.39 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Capricor Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Centessa Pharmaceuticals?

Capricor Therapeutics (NASDAQ:CAPR) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Capricor Therapeutics presently has a consensus target price of $50.30, suggesting a potential upside of 110.37%. Centessa Pharmaceuticals has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Capricor Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Capricor Therapeutics had 7 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 11 mentions for Capricor Therapeutics and 4 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Capricor Therapeutics' score of 0.39 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics' return on equity of -59.27% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Summary

Capricor Therapeutics beats Centessa Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Capricor Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Rhythm Pharmaceuticals currently has a consensus target price of $133.13, suggesting a potential upside of 21.99%. Capricor Therapeutics has a consensus target price of $50.30, suggesting a potential upside of 110.37%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

21.7% of Capricor Therapeutics shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Capricor Therapeutics had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 11 mentions for Capricor Therapeutics and 5 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.61 beat Capricor Therapeutics' score of 0.39 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Capricor Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Capricor Therapeutics' return on equity of -59.27% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Capricor Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$217.17M	34.44	-$196.54M	-$3.13	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

Summary

Capricor Therapeutics beats Rhythm Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Belite Bio?

Capricor Therapeutics (NASDAQ:CAPR) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Belite Bio's return on equity of -13.14% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Belite Bio	N/A	-13.14%	-12.88%

Capricor Therapeutics currently has a consensus target price of $50.30, suggesting a potential upside of 110.37%. Belite Bio has a consensus target price of $203.00, suggesting a potential upside of 35.22%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Belite Bio is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

In the previous week, Capricor Therapeutics had 9 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for Capricor Therapeutics and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.57 beat Capricor Therapeutics' score of 0.39 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market.

Summary

Capricor Therapeutics beats Belite Bio on 9 of the 14 factors compared between the two stocks.

How does Capricor Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Cogent Biosciences currently has a consensus target price of $43.73, suggesting a potential upside of 15.53%. Capricor Therapeutics has a consensus target price of $50.30, suggesting a potential upside of 110.37%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Cogent Biosciences is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

In the previous week, Capricor Therapeutics had 9 more articles in the media than Cogent Biosciences. MarketBeat recorded 11 mentions for Capricor Therapeutics and 2 mentions for Cogent Biosciences. Capricor Therapeutics' average media sentiment score of 0.39 beat Cogent Biosciences' score of 0.38 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

21.7% of Capricor Therapeutics shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Capricor Therapeutics' return on equity of -59.27% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Summary

Capricor Therapeutics beats Cogent Biosciences on 11 of the 14 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPR vs. The Competition

Export

Metric	Capricor Therapeutics	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.38B	$8.44B	$6.82B	$12.35B
Dividend Yield	N/A	2.47%	2.67%	6.11%
P/E Ratio	-10.30	16.21	25.82	24.22
Price / Sales	N/A	5.69	551.75	101.49
Price / Cash	N/A	18.07	29.09	36.93
Price / Book	4.32	3.45	10.90	6.43
Net Income	-$105.04M	$226.25M	$3.58B	$336.87M
7 Day Performance	-18.51%	2.07%	2.42%	0.27%
1 Month Performance	-20.19%	-3.31%	0.14%	-0.93%
1 Year Performance	114.44%	0.64%	35.46%	29.64%

Capricor Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPR Capricor Therapeutics	2.3137 of 5 stars	$23.91 -9.6%	$50.30 +110.4%	+137.1%	$1.38B	N/A	N/A	101	Gap Up
MIRM Mirum Pharmaceuticals	2.201 of 5 stars	$101.55 +0.5%	$139.80 +37.7%	+141.9%	$6.16B	$521.31M	N/A	140	Positive News Gap Down
CNTA Centessa Pharmaceuticals	1.7044 of 5 stars	$39.75 0.0%	$41.33 +4.0%	N/A	$6.15B	$15M	N/A	200	Short Interest Decrease
RYTM Rhythm Pharmaceuticals	2.7203 of 5 stars	$89.72 +0.0%	$133.13 +48.4%	+75.1%	$6.15B	$189.76M	N/A	140
BLTE Belite Bio	3.2604 of 5 stars	$138.19 -4.2%	$203.00 +46.9%	+151.9%	$5.78B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPR) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Competitors

CAPR vs. MIRM, CNTA, RYTM, BLTE, and COGT

How does Capricor Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Capricor Therapeutics compare to Centessa Pharmaceuticals?

Summary

How does Capricor Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Capricor Therapeutics compare to Belite Bio?

Summary

How does Capricor Therapeutics compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Competitors

CAPR vs. MIRM, CNTA, RYTM, BLTE, and COGT

How does Capricor Therapeutics compare to Mirum Pharmaceuticals?

Which has more risk and volatility, CAPR or MIRM?

Which has higher valuation and earnings, CAPR or MIRM?

Do institutionals and insiders have more ownership in CAPR or MIRM?

Do analysts prefer CAPR or MIRM?

Is CAPR or MIRM more profitable?

Does the media prefer CAPR or MIRM?

Summary

How does Capricor Therapeutics compare to Centessa Pharmaceuticals?

Do insiders & institutionals hold more shares of CAPR or CNTA?

Which has preferable earnings and valuation, CAPR or CNTA?

Do analysts recommend CAPR or CNTA?

Which has more volatility & risk, CAPR or CNTA?

Does the media refer more to CAPR or CNTA?

Is CAPR or CNTA more profitable?

Summary

How does Capricor Therapeutics compare to Rhythm Pharmaceuticals?

Do analysts rate RYTM or CAPR?

Do institutionals & insiders hold more shares of RYTM or CAPR?

Does the media prefer RYTM or CAPR?

Is RYTM or CAPR more profitable?

Which has more risk and volatility, RYTM or CAPR?

Which has higher earnings and valuation, RYTM or CAPR?

Summary

How does Capricor Therapeutics compare to Belite Bio?

Is CAPR or BLTE more profitable?

Do analysts rate CAPR or BLTE?

Do insiders & institutionals hold more shares of CAPR or BLTE?

Which has better valuation & earnings, CAPR or BLTE?

Does the media refer more to CAPR or BLTE?

Which has more volatility and risk, CAPR or BLTE?

Summary

How does Capricor Therapeutics compare to Cogent Biosciences?

Do analysts recommend COGT or CAPR?

Which has higher valuation & earnings, COGT or CAPR?

Does the media prefer COGT or CAPR?

Which has more volatility & risk, COGT or CAPR?

Do insiders and institutionals hold more shares of COGT or CAPR?

Is COGT or CAPR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools